Pulmonary Hypertension: “You Take My Breath Away”

  • Jennifer CottonEmail author
  • Eric Adkins


Pulmonary hypertension is a disease process affecting the pulmonary vasculature and right heart with a high morbidity and mortality. Increases in pulmonary vasculature pressures cause both diastolic and systolic dysfunction of the right ventricle. The resulting preload-dependent output of the right ventricle makes patients sensitive to small fluid losses. The dilation of the right ventricle also causes increases in fluid volume to overstretch the right ventricle and reduce contractility. As a result, pulmonary hypertension patients live within a narrow margin of fluid balance. To aid right heart function many patients are continuously infused medication to reduce pulmonary resistance and right ventricle afterload. However, this also comes with complications, especially when there is an abrupt failure in the delivery of these medications. Overall, these are difficult patients to manage during acute episodes of decompensation due to their marginal cardiac function, hypersensitivity to changes in volume status, and limited usefulness of many exam findings or tests used to assess volume status.


Pulmonary hypertension Right heart failure Respiratory distress Cardiac emergencies Pulmonary emergencies Critical care Emergency medicine Ultrasound 


Disclosure Statement

The authors of this chapter report no significant disclosures.


  1. 1.
    Winters ME. Pulmonary hypertension. In: Tintinalli J, editor. Tintinalli’s emergency medicine. 8th ed. New York: McGraw-Hill Medical; 2016.Google Scholar
  2. 2.
    Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55.CrossRefGoogle Scholar
  3. 3.
    Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37:67.CrossRefGoogle Scholar
  4. 4.
    Ghio S, Pica S, Klersy C, et al. Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy. Open Heart. 2016;3:e000408.CrossRefGoogle Scholar
  5. 5.
    Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146:449.CrossRefGoogle Scholar
  6. 6.
    Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician. 2001;63(9):1789–98.PubMedGoogle Scholar
  7. 7.
    Gayat E, Mebazaa A. Pulmonary hypertension in critical care. Curr Opin Crit Care. 2011;17:439–44; Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62:D60.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Emergency Medicine, Department of SurgeryUniversity of Utah HospitalSalt Lake CityUSA
  2. 2.Department of Emergency MedicineWexner Medical Center at The Ohio State UniversityColumbusUSA

Personalised recommendations